Financial News · Live Terminal

Page 475 of 534

Avino Silver & Gold Mines Reports Lower Q1 Silver, Gold, Copper Production

Avino Silver & Gold Mines' (ASM) Q1 silver equivalent production declined 10% to 568,112 ounces from 631,249 ounces a year earlier, the company said Thursday.Silver production edged down 1% to 263,057 ounces, while gold output fell 17% to 1,851 ounces, Avino said.The company said its copper production decreased 16% to 1.34 million pounds, while mill throughput increased 11% from a year earlier.The company said production was affected by planned mining in lower-grade areas during the quarter.Avino said it plans to release Q1 financial report after market close on May 13.Price: $7.28, Change: $-0.04, Percent Change: -0.55%

$ASM

Wire109d ago

OSI Systems Wins $235 Million Defense Contract

OSI Systems' (OSIS) security division won a contract with a ceiling value of $235 million for the production and integration of a homeland defense over the horizon radar, or OTHR, transit subsystem, the company said Thursday.The initial program executive is valued at $46 million, with additional funding to continue over the program schedule, OSI System said. The subsystem is intended to enable long-range target tracking, the company added.Price: $295.76, Change: $+3.24, Percent Change: +1.11%

$OSIS

Wire109d ago

Deutsche Bank Raises Price Target on Moody's to $575 From $558, Keeps Buy Rating

Moody's (MCO) has an average rating of overweight and mean price target of $540.35, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $459.63, Change: $-7.25, Percent Change: -1.55%

$MCO

Wire109d ago

Seaport Global Adjusts Price Target on Steel Dynamics to $245 From $195, Maintains Buy Rating

Steel Dynamics (STLD) has an average rating of overweight and mean price target of $230.50, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $227.23, Change: $-0.23, Percent Change: -0.10%

$STLD

Wire109d ago

Morgan Stanley Adjusts Price Target on Campbell's to $23 From $25, Maintains Equalweight Rating

Campbell's (CPB) has an average rating of hold and mean price target of $22.53, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $20.79, Change: $-0.03, Percent Change: -0.14%

$CPB

Wire109d ago

Morgan Stanley Adjusts Price Target on J.M. Smucker to $104 From $118, Maintains Equalweight Rating

J.M. Smucker (SJM) has an average rating of overweight and mean price target of $119.60, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $94.82, Change: $-0.15, Percent Change: -0.16%

$SJM

Wire109d ago

Benchmark Adjusts Price Target on Charter Communications to $435 From $455, Maintains Buy Rating

Charter Communications (CHTR) has an average rating of hold and mean price target of $298.21, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $247.28, Change: $+4.79, Percent Change: +1.97%

$CHTR

Wire109d ago

Deutsche Bank Lowers Price Target on CME Group to $322 From $342, Keeps Buy Rating

CME Group (CME) has an average rating of hold and mean price target of $312.73, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $285.37, Change: $-0.34, Percent Change: -0.12%

$CME

Wire109d ago

Air Products Maintains Quarterly Dividend at $1.81 a Share; Payable Aug. 10 to Shareholders of Record as of July 1

$APD

Wire109d ago

Deutsche Bank Raises Price Target on Zurn Elkay Water Solutions to $56 From $53, Keeps Buy Rating

Zurn Elkay Water Solutions (ZWS) has an average rating of overweight and mean price target of $56.22, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $53.41, Change: $+0.93, Percent Change: +1.76%

$ZWS

Wire109d ago

Deutsche Bank Lifts Price Target on Masco to $77 From $75, Keeps Hold Rating

Masco (MAS) has an average rating of overweight and mean price target of $80.44, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $75.12, Change: $+1.16, Percent Change: +1.58%

$MAS

Wire109d ago

Deutsche Bank Raises Price Target on Boeing to $233 From $223, Keeps Hold Rating

Boeing (BA) has an average rating of overweight and mean price target of $267.68, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $232.99, Change: $+1.71, Percent Change: +0.74%

$BA

Wire109d ago

Tilray Brands Says Cannabis Rescheduling Furthers Research, Access; Shares Rise Pre-Bell

Tilray Brands (TLRY) said Thursday that the Trump administration's move to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act furthers medical cannabis clinical research, patient access, and industry standardization.The rescheduling represents an inflection point for US drug policy, and Tilray will participate in the emerging regulated medical cannabis market in the country, the company said.Shares of Tilray Brands were up 14% in Thursday premarket trading.Other cannabis stocks like Canopy Growth (CGC), Cronos (CRON), High Tide (HITI), SNDL (SNDL), and Aurora Cannabis (ACB) were also higher following the news of cannabis rescheduling.

$ACB$CGC$CRON$HITI$SNDL$TLRY

Wire109d ago

HomeTrust Bancshares Reports Q1 Earnings, Revenue; Quarterly Dividend Raised

HomeTrust Bancshares (HTB) reported Q1 earnings Thursday of $0.99 per diluted share.Analysts polled by FactSet expected $0.82.Revenue for the quarter ended March 31, expressed as the sum of net interest income and total noninterest income, was $54.3 million.Four analysts surveyed by FactSet expected $51.8 million.Additionally, the company said it has raised its quarterly dividend by 15.4% to $0.15 per common share, payable May 28 to shareholders of record as of May 14.Shares of HomeTrust Bancshares were up 2% in Thursday premarket activity.Price: $45.55, Change: $+0.89, Percent Change: +1.99%

$HTB

Wire109d ago

LSI Industries Fiscal Q3 Adjusted EPS, Sales Rise; Shares Up Pre-Bell

LSI Industries (LYTS) reported fiscal third-quarter adjusted earnings Thursday of $0.28 per diluted share, up from $0.20 a year earlier.Three analysts polled by FactSet expected $0.18.Net sales for the quarter ended March 31 were $150.5 million, up from $132.5 million a year earlier.Three analysts surveyed by FactSet expected $138.7 million.The company maintained its quarterly dividend at $0.05 a share, payable May 12 to holders of record on May 4.Shares of the company rose 6.2% in Thursday premarket trading.

$LYTS

Wire109d ago

Iridium Communications Q1 Net Income Declines, Revenue Increases

Iridium Communications (IRDM) reported Q1 net income Thursday of $0.20 per diluted share, down from $0.27 a year earlier.Analysts polled by FactSet expected $0.33.Revenue for the quarter ended March 31 was $219.1 million, up from $214.9 million a year earlier.Revenue for the quarter ended March 31 was $219.1 million, up from $214.9 million a year earlier.Analysts surveyed by FactSet expected $218.4 million.Shares of the company were down more than 4% in recent premarket activity Thursday.Price: $38.61, Change: $-1.79, Percent Change: -4.43%

$IRDM

Wire109d ago

Huntington Bancshares Q1 Adjusted Earnings, Revenue Rise

Huntington Bancshares (HBAN) reported Q1 adjusted earnings Thursday of $0.37 per diluted share, up from $0.34 a year earlier.Analysts polled by FactSet expected $0.35.Revenue, expressed as the sum of net interest income and total non-interest income, was $2.57 billion for the quarter ended March 31, compared with $1.92 billion a year earlier.Analysts surveyed by FactSet expected $2.57 billion.Shares of the company were up more than 1% in Thursday premarket activity.Price: $16.61, Change: $-0.21, Percent Change: -1.25%

$HBAN

Wire109d ago

West Pharmaceutical Q1 Non-GAAP Earnings, Net Sales Rise; Issues Q2 Guidance -- Shares Rise Pre-Bell

West Pharmaceutical Services (WST) reported Q1 non-GAAP earnings Thursday of $2.13 per diluted share, up from $1.45 a year earlier.Analysts polled by FactSet expected $1.68.Net sales for the quarter ended March 31 were $844.9 million, compared with $698 million a year earlier.Analysts surveyed by FactSet expected $780.3 million.The company expects Q2 adjusted EPS of $2.05 to $2.12. Analysts surveyed by FactSet expect $2.Revenue for the quarter is projected to be between $830 million and $850 million. Analysts polled by FactSet expect $818.4 million.For 2026, the company now expects 2026 adjusted EPS of $8.40 to $8.75, compared with its prior guidance of $7.85 to $8.20. Analysts polled by FactSet expect $8.01.Revenue for the full-year is now projected to be about $3.30 billion to $3.35 billion, compared with its earlier outlook of $3.22 billion to $3.28 billion. Analysts polled by FactSet expect $3.25 billion.Shares of the company were over 10% higher in Thursday premarket activity.Price: $310.00, Change: $+35.59, Percent Change: +12.97%

$WST

Wire109d ago

Altimmune Prices $225 Million Public Offering; Shares Fall Pre-Bell

Altimmune (ALT) said Wednesday it priced its underwritten public offering, consisting of about 64.3 million common shares and accompanying warrants to buy an about 64.3 million common shares and pre-funded warrants to buy up to about 10.8 million common shares and accompanying warrants to buy about 10.8 million common shares.The combined offering price of each common share and accompanying warrant is $3, while the combined offering price of each pre-funded warrant and accompanying common stock warrant is $2.999.The offering is set to close around Friday.Gross proceeds from the offering, set to close around Friday, are estimated to be about $225 million.Altimmune said it plans to use the net proceeds to fund its upcoming phase 3 trial in metabolic dysfunction-associated steatohepatitis, as well as for working capital and general corporate purposes.The company's shares were down over 13% during Thursday premarket activity.Price: $3.00, Change: $-0.47, Percent Change: -13.45%

$ALT

Wire109d ago

Core Scientific Subsidiary Prices $3.3 Billion Private Notes Offering; Shares Down Premarket

Core Scientific (CORZ) said its wholly-owned subsidiary, Core Scientific Finance I, priced an offering of $3.3 billion of 7.750% senior secured notes due 2031 at 99.250% of the principal.The unit plans to use the proceeds to fund a debt service reserve account and distribute the remaining funds to its parent, Core Scientific said late Wednesday. The company intends to use a portion of the net proceeds to repay delayed loans from its 364-day credit facility.The notes will be sold in a private offering to institutional buyers. The offering is expected to close on May 6.Shares of Core Scientific were down 1.3% in Thursday's premarket activity.Price: $20.91, Change: $-0.28, Percent Change: -1.32%

$CORZ

Showing 9481-9500 of 10672